Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase…
Biotechnology
US, Cardiff-by-the-Sea [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Viracta Therapeutics, Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDViracta Therapeutics, Inc. can't present revenue by segment